A Remotely Delivered, GLP-1RA-Supported Specialist Weight Management Program: 12 Month Outcomes From a Retrospective Service Evaluation (Preprint) DOI Creative Commons
Rebecca Richards, Michael Whitman, Gina Wren

и другие.

JMIR Formative Research, Год журнала: 2025, Номер unknown

Опубликована: Фев. 14, 2025

Limited access to specialist weight management services (SWMS) restricts the implementation of novel obesity pharmacotherapy like GLP-1 receptor agonists (GLP-1RAs) in United Kingdom's (UK) National Health Service (NHS). Second Nature, a commercial digital health company, offers remotely delivered program combining GLP-1RA medication (semaglutide) with behavioural support, potentially providing scalable solution. However, evidence for long-term effectiveness this real-world context is limited. To evaluate 12-month effectiveness, feasibility, acceptability, and potential cost-effectiveness Nature's remotely-delivered, semaglutide-supported program. This retrospective service evaluation analysed data from participants initiating between September December 2023. The primary outcome was change at 12 months among available (completers). Secondary outcomes included retention, engagement (measured by application 'Home' screen views), changes, side effects, participant experience (qualitative analysis), comparative cost analysis against NHS SWMS. An 'active subscription' defined as maintaining paid subscription full months. Descriptive statistics paired two-tailed t-tests evaluated outcomes. Data 341 were baseline (82.8% women; mean age 49.0 years, SD 11.1; BMI 37.9 kg/m², 6.9). At months, 39.6% (n=135) maintained an active subscription, while 60.4% (n=206) had become inactive. Weight 179 (52.5% cohort; 100% 19.4% inactive participants). Among completers who loss 18.1 kg (SD 9.5; P<.001), representing 17.3% starting weight. Overall, 77.7% achieved ≥10% 61.5% ≥15%. Program declined over time. Side effects also decreased, 69.6% respondents reporting none month 12. Most completing survey reported positive (34.2%) or neutral (56.7%) experiences. suggests that remotely-delivered GLP-1RA-supported can achieve significant remaining engaged high rate withdrawal limits generalizability. appears feasible, acceptable completers, cost-effective. Further research, ideally within public healthcare settings using intent-to-treat analyses, needed confirm clinical outcomes, assess sustained results, understand factors influencing retention.

Язык: Английский

A Remotely Delivered, GLP-1RA-Supported Specialist Weight Management Program: 12 Month Outcomes From a Retrospective Service Evaluation (Preprint) DOI Creative Commons
Rebecca Richards, Michael Whitman, Gina Wren

и другие.

Опубликована: Фев. 14, 2025

BACKGROUND Limited access to specialist weight management services (SWMS) restricts the implementation of novel obesity pharmacotherapy in United Kingdom’s (UK) National Health Service (NHS). Remote delivery GLP-1 receptor agonist (GLP-1RA) medication with digital behavioural support could provide a scalable solution, but evidence for long-term effectiveness is limited OBJECTIVE To evaluate effectiveness, feasibility, acceptability and potential cost-effectiveness Second Nature's remotely-delivered, semaglutide-supported program over 12 months METHODS Retrospective data were extracted participants who initiated intervention between September December 2023. Primary outcome was change at months. Secondary outcomes included behavioral changes, side effects, engagement, participant experience comparative cost analysis against NHS SWMS. Descriptive statistics paired two-tailed t-tests evaluated outcomes. Content used qualitative data. RESULTS Of 341 (82.8% women; mean age 49.0 years, SD 11.1; baseline BMI 37.9 kg/m², 6.9). Participants active subscriptions (39.6%, n=135) achieved 20.0 kg (19.1%, ,P<.001) loss versus 12.4 (11.9%) inactive subscriptions. Overall, 77.7% ≥10% 61.5% ≥15%. Program engagement declined from 113 (SD 78.4) home screen views month 1 25 29.06) 12. Side effects decreased time, 69.6% reporting none by Most reported positive (34.2%) or neutral (56.7%) experiences The costs estimated 30-40% current SWMS, projecting savings £1.5m-£1.8m per 100,000 population CONCLUSIONS This evaluation suggests that remotely-delivered GLP-1RA-supported can be effective, feasible, acceptable cost-effective people living obesity. Further research within public healthcare settings needed clinical assess sustained results continuation discontinuation medication.

Язык: Английский

Процитировано

0
Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management: A Retrospective Service Evaluation of GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy in the United Kingdom (Preprint) DOI Creative Commons
Hans Johnson, David Huang, Vivian N. Liu

и другие.

Journal of Medical Internet Research, Год журнала: 2025, Номер 27, С. e69466 - e69466

Опубликована: Фев. 28, 2025

Background Obesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide tirzepatide), have led to significant weight loss among users. Digital platforms offering behavioral support may enhance the effectiveness of these medications. Objective This retrospective service evaluation investigated impact engagement with an app-based digital program on outcomes individuals using GLP-1 (semaglutide) (tirzepatide) in United Kingdom over 5 months. Methods Data were collected from Voy platform between February 2023 August 2024. Participants adults aged 18-75 years BMI ≥30 or ≥27.5 kg/m2 presence obesity-related comorbidities who initiated management involving semaglutide tirzepatide. Engagement was defined based attendance at coaching sessions, frequency app use, regular tracking. categorized “engaged” “nonengaged” accordingly. Weight assessed period up Statistical analyses included chi-square tests, independent t Kaplan-Meier survival analysis, calculations Cohen d for effect sizes. Results A total 57,975 participants 31,407 (54.2%) classified engaged 26,568 (45.8%) nonengaged. Engaged achieved significantly greater each time point. At month 3, had mean 9% (95% CI 9.1%) compared 5.9% 6%) nonengaged (P<.001), representing difference 3.1 percentage points 3.1% 3.1%). size 0.89 indicated large effect. 5, 11.53% 11.5% 11.6%) 8% 7.9% 8%) (P<.001). 0.56 moderate tirzepatide more than those (13.9%, 95% 13.5% 14.3% vs 9.5%, 9.2% 9.7%; P<.001). The proportion achieving ≥5%, ≥10%, ≥15% higher group corresponding months 3 respectively Conclusions enhances agonists. combination pharmacotherapy offers promising strategy promote supported self-care journey seeking clinically effective obesity interventions.

Язык: Английский

Процитировано

0
A Remotely Delivered, GLP-1RA-Supported Specialist Weight Management Program: 12 Month Outcomes From a Retrospective Service Evaluation (Preprint) DOI Creative Commons
Rebecca Richards, Michael Whitman, Gina Wren

и другие.

JMIR Formative Research, Год журнала: 2025, Номер unknown

Опубликована: Фев. 14, 2025

Limited access to specialist weight management services (SWMS) restricts the implementation of novel obesity pharmacotherapy like GLP-1 receptor agonists (GLP-1RAs) in United Kingdom's (UK) National Health Service (NHS). Second Nature, a commercial digital health company, offers remotely delivered program combining GLP-1RA medication (semaglutide) with behavioural support, potentially providing scalable solution. However, evidence for long-term effectiveness this real-world context is limited. To evaluate 12-month effectiveness, feasibility, acceptability, and potential cost-effectiveness Nature's remotely-delivered, semaglutide-supported program. This retrospective service evaluation analysed data from participants initiating between September December 2023. The primary outcome was change at 12 months among available (completers). Secondary outcomes included retention, engagement (measured by application 'Home' screen views), changes, side effects, participant experience (qualitative analysis), comparative cost analysis against NHS SWMS. An 'active subscription' defined as maintaining paid subscription full months. Descriptive statistics paired two-tailed t-tests evaluated outcomes. Data 341 were baseline (82.8% women; mean age 49.0 years, SD 11.1; BMI 37.9 kg/m², 6.9). At months, 39.6% (n=135) maintained an active subscription, while 60.4% (n=206) had become inactive. Weight 179 (52.5% cohort; 100% 19.4% inactive participants). Among completers who loss 18.1 kg (SD 9.5; P<.001), representing 17.3% starting weight. Overall, 77.7% achieved ≥10% 61.5% ≥15%. Program declined over time. Side effects also decreased, 69.6% respondents reporting none month 12. Most completing survey reported positive (34.2%) or neutral (56.7%) experiences. suggests that remotely-delivered GLP-1RA-supported can achieve significant remaining engaged high rate withdrawal limits generalizability. appears feasible, acceptable completers, cost-effective. Further research, ideally within public healthcare settings using intent-to-treat analyses, needed confirm clinical outcomes, assess sustained results, understand factors influencing retention.

Язык: Английский

Процитировано

0